22 hours ago | News
Watson Pharmaceuticals Inc. said Wednesday it settled a patent lawsuit brought by a unit of Johnson & Johnson over a generic version of the birth control drug Ortho Tri-Cyclen Lo.
|
Feb 8 | News
SAN DIEGO (AP) — Diagnostics company Illumina Inc. again rejected a $5.7 billion offer from Roche AG on Tuesday, saying the Swiss drugmaker's bid was "grossly inadequate."
|
Feb 8 | News
Sanofi and Bristol-Myers Squibb Company announced today that Apotex has made payment in the amount of $442,209,362 to Sanofi and Bristol-Myers Squibb to satisfy the damages ruling of the Plavix(R) (clopidogrel bisulfate) patent infringement case against Apotex.
|
Feb 7 | News
NEW YORK (AP) — Shares of Anacor Pharmaceuticals Inc. dropped more than 8 percent Monday after the company said its partner GlaxoSmithKline PLC stopped enrolling patients in studies of an anti-infection drug.
|
Feb 7 | News
SAN DIEGO (AP) — Diabetes drug maker Amylin Pharmaceuticals Inc. reported a larger fourth-quarter loss Monday after it ended a partnership with Eli Lilly & Co., which gave Amylin all the rights to the drug Byetta and newly approved Bydureon.
|
Feb 7 | News
LONDON (AP) — GlaxoSmithKline PLC says it has returned to profit in the fourth quarter as restructuring costs and overheads declined.
|
Feb 6 | News
Xceleron, a company involved in accelerating drug development using ultra-sensitive bioanalytical analyses, today announced that existing investors Albion Ventures and Solon Ventures have invested $2.4MM to locate all of the company’s business in its custom-built facility in Germantown, MD which is expected to be fully operational by 31st March 2012.
|
Feb 6 | News
Valeant Pharmaceuticals International, Inc. today announced that it has completed the divestiture of 1% clindamycin and 5% benzoyl peroxide gel (IDP-111), a generic version of Benzaclin, and 5% fluorouracil cream, (5-FU), an authorized generic of Efudex, to Mylan Inc.
|
Feb 6 | News
NEW YORK (AP) — Shares of Gilead Sciences Inc. jumped Friday after the company reported further progress of GS-7977, a newly-acquired hepatitis C treatment still in clinical testing.
|
Feb 3 | News
For drugmakers, the golden era of the 1990s and early part of the last decade, when they seemed to effortlessly churn out new multibillion-dollar pills for the masses along with double-digit quarterly profit increases, is not even in the rearview mirror any more.
|